肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Biomaterials：基于GO的靶向FSHR的纳米复合物或可用于乳腺癌转移患者的治疗

2017-10-22 MedSci MedSci原创

GO乳腺癌
关注

血管发生，即新血管生成的形成，是癌症起始、进展和转移过程中的关键过程。靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中。本研究中，研究人员在乳腺癌大鼠模型中检测了纳米氧化烯氧化物（GO）与促卵泡激素受体（FSHR）单克隆抗体（mAb）耦合后靶向肿瘤的效果。研究已证实FSHR是一种高度选择性的肿瘤脉管系统标志物，原发性和转移性肿瘤中含量丰富。原子力显微镜（AFM）、TEM和动态激光散射（DLS）检

血管发生，即新血管生成的形成，是癌症起始、进展和转移过程中的关键过程。靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中。

本研究中，研究人员在乳腺癌大鼠模型中检测了纳米氧化烯氧化物（GO）与促卵泡激素受体（FSHR）单克隆抗体（mAb）耦合后靶向肿瘤的效果。研究已证实FSHR是一种高度选择性的肿瘤脉管系统标志物，原发性和转移性肿瘤中含量丰富。

原子力显微镜（AFM）、TEM和动态激光散射（DLS）检测这些功能化的GO纳米共轭物，现实其直径为〜120nm。将64Cu作为放射性标记物引入，通过正电子发射断层扫描（PET）成像可以显示这些GO耦合物。通过静脉注射单甲虫绿色荧光素酶转染的MDA-MB-231乳腺癌诱导肿瘤生长建立乳腺癌肺转移模型，并通过生物发光成像（BLI）进行监测。

体外和体内系统性研究探究了GO耦合物的稳定性、靶向功效和特异性及组织分布。流式细胞术和荧光显微镜检查证实FSHR-mAb与GO耦合物结合特异性靶向细胞FSHR。与非靶向GO耦合物（64Cu-NOTA-GO）相比，肺内cbgLuc-MDA-MB-231结节中可更有效和持续摄取64Cu-NOTA-GO-FSHR-mAb。组织学评估也证实了GO-FSHR-mAb共轭体在肿瘤中早期时间点的脉管系统中积累，而在肝脏和脾脏中非特异性捕获。

此外，这些GO耦合物可作为较好的药物载体（例如，多柔比星[DOX]，756mg/g）。荧光成像现实，DOX负载的GO-FSHR-mAb在cbgLuc-MDA-MB-231转移位点的药物递送效率提高。

总之，该研究结果表明，这种靶向FSHR的基于GO的纳米平台可以作为癌症早期转移检测和靶向递送治疗药物的有用工具。

原始出处：

Dongzhi Yang, Liangzhu Feng, et al., In Vivo Targeting of Metastatic Breast Cancer via Tumor Vasculature-Specific Nano-Graphene Oxide. Biomaterials. Author manuscript; available in PMC 2017 Oct 17.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049984, encodeId=00ce2049984d9, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Sep 29 02:56:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910601, encodeId=6f99191060130, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sun Nov 19 03:56:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917721, encodeId=e9ad191e7219e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 10 08:56:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590305, encodeId=06f11590305ff, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Oct 24 07:56:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255126, encodeId=097925512678, content=血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Oct 22 17:11:45 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2018-09-29 zhangyxzsh

    #Biomaterials#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2049984, encodeId=00ce2049984d9, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Sep 29 02:56:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910601, encodeId=6f99191060130, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sun Nov 19 03:56:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917721, encodeId=e9ad191e7219e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 10 08:56:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590305, encodeId=06f11590305ff, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Oct 24 07:56:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255126, encodeId=097925512678, content=血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Oct 22 17:11:45 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-11-19 yang0210

    #复合物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2049984, encodeId=00ce2049984d9, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Sep 29 02:56:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910601, encodeId=6f99191060130, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sun Nov 19 03:56:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917721, encodeId=e9ad191e7219e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 10 08:56:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590305, encodeId=06f11590305ff, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Oct 24 07:56:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255126, encodeId=097925512678, content=血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Oct 22 17:11:45 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-11-10 sunylz

    #Bio#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2049984, encodeId=00ce2049984d9, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Sep 29 02:56:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910601, encodeId=6f99191060130, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sun Nov 19 03:56:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917721, encodeId=e9ad191e7219e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 10 08:56:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590305, encodeId=06f11590305ff, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Oct 24 07:56:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255126, encodeId=097925512678, content=血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Oct 22 17:11:45 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-24 linagood

    #癌转移#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2049984, encodeId=00ce2049984d9, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Sep 29 02:56:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910601, encodeId=6f99191060130, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sun Nov 19 03:56:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917721, encodeId=e9ad191e7219e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Nov 10 08:56:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590305, encodeId=06f11590305ff, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Oct 24 07:56:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255126, encodeId=097925512678, content=血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Oct 22 17:11:45 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 有备才能无患

    血管发生.即新血管生成的形成.是癌症起始.进展和转移过程中的关键过程.靶向血管生成标志物可更有效地将纳米材料输送至肿瘤中.

    0